Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2000 Nov;164(5):1538-42.

Phase II study of paclitaxel and cisplatin for advanced urothelial cancer

P A Burch  1 , R L Richardson, S S Cha, D J Sargent, H C Pitot 4th, J S Kaur, J K Camoriano
Affiliations
  • PMID: 11025699
Clinical Trial

Phase II study of paclitaxel and cisplatin for advanced urothelial cancer

P A Burch et al. J Urol. 2000 Nov.

Abstract

Purpose: We examined the role of paclitaxel and cisplatin as first line therapy for metastatic urothelial cancer.

Materials and methods: A total of 34 patients were enrolled in this study, and all were eligible for treatment and assessable for response. Patients received 135 mg./m.2 paclitaxel intravenously for 3 hours followed by 70 mg./m.2 cisplatin for 2 hours every 3 weeks to a maximum of 6 cycles.

Results: Of the patients 70% experienced a major response to treatment, which was partial/regression in 38% and complete in 32%. Toxicity was manageable with no episodes of grade 4 leukopenia or thrombocytopenia. Nonhematological toxicities included primarily nausea, anorexia and neuropathy, which rarely were severe.

Conclusions: This regimen of paclitaxel and cisplatin is effective, safe and convenient to administer in an outpatient setting for advanced urothelial cancer.

PubMed Disclaimer

Publication types

MeSH terms